NCT04740814 - A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 11, 2021

Primary Completion Date

January 24, 2022

Study Completion Date

June 27, 2022

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Certolizumab pegol

"* Pharmaceutical form: Solution for injection~* Route of administration: Subcutaneous Subjects will receive certolizumab pegol in a pre-specified sequence during the study."

Trial Locations (14)

16635

Ra0138 10025, Duncansville

Ra0138 1003, Duncansville

20850

Ra0138 1014, Rockville

33324

Ra0138 1004, Plantation

34684

Ra0138 1015, Palm Harbor

38119

Ra0138 1016, Memphis

40504

Ra0138 1001, Lexington

75231

Ra0138 1010, Dallas

77375

Ra0138 1011, Tomball

78731

Ra0138 1007, Austin

85032

Ra0138 1009, Phoenix

87102

Ra0138 1005, Albuquerque

91722

Ra0138 1002, Covina

91786

Ra0138 1008, Upland

All Listed Sponsors

lead

UCB Biopharma SRL

INDUSTRY